Adjuvant activities of a mutant LT-IIb enterotoxin lacking binding to ganglioside GD1a

UB microbiologists have developed a mutant heat-labile enterotoxin (LT-IIb) that demonstrates promising adjuvant activity and appears to overcome the limitations and concerns related to various mucosal adjuvants currently under investigation. The abi lity of the mutant LT-IIb to stimulate mucosal and systemic immune responses against co-administered vaccine antigens in the absence of ganglioside binding is certainly advantageous, as it offers the potential to develop a safe and effective mucosal (intranasal or oral) adjuvant for human use. Immune stimulation by this mutant enterotoxin should avoid problems of neural uptake and transmission to the brain, as well as enterotoxicity, which have precluded the use of other enterotoxin-based adjuv ants in human vaccines.

Summary of potential advantages:

Lack of enterotoxicity Diminished or abrogated likelihood for neural uptake and retrograde trafficking Adjuvant activity identical to that of the wild-type

Patents:
US 7,455,843

Type of Offer: Licensing



« More Pharmaceutical Patents
« More Medical Patents

---